跳转至内容
Merck
CN

P2670000

吡喹酮

European Pharmacopoeia (EP) Reference Standard

别名:

2-(环己基羰基)-1,2,3,6,7-11b-六氢-4H-吡嗪并-[2,1-a]-异喹啉-4-酮

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H24N2O2
CAS号:
分子量:
312.41
Beilstein:
761557
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

praziquantel

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES字符串

O=C1CN(CC2N1CCc3ccccc23)C(=O)C4CCCCC4

InChI

1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2

InChI key

FSVJFNAIGNNGKK-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Praziquantel EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

危险声明

预防措施声明

危险分类

Aquatic Chronic 3

WGK

WGK 1


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

M J Doenhoff et al.
Parasitology, 136(13), 1825-1835 (2009-03-14)
Treatment with praziquantel (PZQ) has become virtually the sole basis of schistosomiasis control in sub-Saharan Africa and elsewhere, and the drug is reviewed here in the context of the increasing rate that it is being used for this purpose. Attention
Jennifer Keiser et al.
PLoS neglected tropical diseases, 8(7), e2975-e2975 (2014-07-18)
Treatment and morbidity control of schistosomiasis relies on a single drug, praziquantel. Hence, there is a pressing need to develop additional therapeutics against schistosomiasis. The antimalarial drug mefloquine shows antischistosomal activity in animal models and clinical trials, which calls for
Wei Wang et al.
Parasitology research, 111(5), 1871-1877 (2012-10-12)
Since praziquantel was developed in 1970s, it has replaced other antischistosomal drugs to become the only drug of choice for treatment of human schistosomiases, due to high efficacy, excellent tolerability, few and transient side effects, simple administration, and competitive cost.
Wei Wu et al.
Parasitology research, 112(3), 909-915 (2013-01-30)
Schistosomiasis remains a major public health problem with an estimated 200 million people infected in the world, and in China, schistosomiasis japonica is endemic in the south part of the country. In 1960s, before praziquantel was developed, there were about
J M Bygott et al.
Acta tropica, 111(2), 95-101 (2009-04-21)
The role of praziquantel in hydatid disease has not been well defined. This review evaluates the evidence on the use of praziquantel in treatment of cystic hydatid disease from in vitro and in vivo animal studies, human clinical studies and

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门